Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session.Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16.Arhaus
Express News | ACELYRIN Shares Are Trading Higher After Wells Fargo Upgraded the Stock From Equal-Weight to Overweight and Maintained Its $13 Price Target
ACELYRIN Price Target Maintained With a $13.00/Share by Wells Fargo
ACELYRIN Price Target Maintained With a $13.00/Share by Wells Fargo
Wells Fargo Upgrades Acelyrin(SLRN.US) to Buy Rating, Maintains Target Price $13
Wells Fargo analyst Derek Archila upgrades $Acelyrin(SLRN.US)$ to a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 43.2% and a total
Express News | ACELYRIN Inc : Wells Fargo Raises to Overweight From Equal-Weight
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 13%
Although Acelyrin, Inc. (NASDAQ:SLRN) shareholders have enjoyed a great week with the stock up 13%, insiders who sold stock over the past year haven't fared as well. The return on their investment wo
Express News | ACELYRIN, Inc. Announces Positive 16-Week Data From Its Global Phase 2B/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at Eular 2024
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $68
Piper Sandler analyst Yasmeen Rahimi maintains $Acelyrin(SLRN.US)$ with a buy rating, and maintains the target price at $68.According to TipRanks data, the analyst has a success rate of 34.3% and a to
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
H.C. Wainwright Maintains Acelyrin(SLRN.US) With Buy Rating, Raises Target Price to $18
H.C. Wainwright analyst Emily Bodnar maintains $Acelyrin(SLRN.US)$ with a buy rating, and adjusts the target price from $16 to $18.According to TipRanks data, the analyst has a success rate of 37.3% a
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Express News | HC Wainwright & Co. Maintains Buy on Acelyrin, Raises Price Target to $18
Express News | HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $16 Price Target
Buy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising Pipeline
ACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic Advancements
Acelyrin | 10-Q: Quarterly report
Express News | ACELYRIN Inc : H.c. Wainwright Cuts Target Price to $18 From $28
ACELYRIN Is Maintained at Buy by HC Wainwright & Co.
ACELYRIN Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Acelyrin, Lowers Price Target to $18
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
No Data